Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. - Archive ouverte HAL Access content directly
Journal Articles Cancer Research Year : 2010

Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.

(1) , (2, 3, 4, 5) , (6) , (2, 3, 6) , (2, 3) , (2) , (2) , (2, 3) , (2) , (7) , (8, 2, 3) , (2, 3, 7) , (9) , (2, 3) , (1)
1
2
3
4
5
6
7
8
9
Guillaume Ploussard
  • Function : Author
  • PersonId : 760721
  • IdRef : 168065851
Ralph Buttyan
  • Function : Author

Abstract

Expression of class III β-tubulin (βIII-tubulin) correlates with tumor progression and resistance to taxane-based therapies for several human malignancies, but its use as a biomarker of tumor behavior in prostate cancer (PCa) remains largely unexplored. Here, we describe βIII-tubulin immunohistochemical staining patterns of prostate tumors obtained from a broad spectrum of PCa patients, some of whom subsequently received docetaxel therapy for castration-resistant PCa (CRPC). Elevated βIII-tubulin expression was significantly associated with tumor aggressiveness in PCa patients with presumed localized disease, as it was found to be an independent marker of biochemical recurrence after treatment. Additionally, βIII-tubulin expression in tumor cells was an independent predictor of lower overall survival for patients receiving docetaxel-based chemotherapy for CRPC. Manipulation of βIII-tubulin expression in human PCa cell lines using a human βIII-tubulin expression vector or βIII-tubulin small interfering RNA altered cell survival in response to docetaxel treatment in a manner that supports a role for βIII-tubulin expression as a mediator of PCa cell resistance to docetaxel therapy. Our findings suggest a role for βIII-tubulin as candidate theranostic biomarker to predict the response to docetaxel-based chemotherapy as well as to target for treatment of docetaxel-resistant CRPC.
Fichier principal
Vignette du fichier
inserm-00536081_edited.pdf (540.45 Ko) Télécharger le fichier
Vignette du fichier
Class_III_--Tubulin_Expression_Predicts_Prostate_Tumor_Aggressiveness_and_Patient_Response_to_Docetaxel-Based_Chemotherapy.pdf (15.45 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-00536081 , version 1 (03-11-2011)

Identifiers

Cite

Guillaume Ploussard, Stéphane Terry, Pascale Maillé, Yves Allory, Nanor Sirab, et al.. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.. Cancer Research, 2010, 70 (22), pp.9253-64. ⟨10.1158/0008-5472.CAN-10-1447⟩. ⟨inserm-00536081⟩
142 View
505 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More